White Plains, Dec. 10, 2024 (GLOBE NEWSWIRE) -- White Plains, NY – December 10, 2024 – Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and micro-interventional approaches for the treatment of ophthalmic diseases, announced one-year results for the first 100 eyes enrolled in the CREST Registry, a real-world, prospective, observational study evaluating the outcomes of bio-interventional procedures in patients with open angle glaucoma (OAG). The study, titled "One-Year Safety and Effectiveness of Bio-Interventional Cyclodialysis and Scleral Reinforcement in Open-Angle Glaucoma Patients," was recently published in Clinical Ophthalmology, and reported on the safety and effectiveness outcomes of micro-invasive cyclodialysis cleft formation with the CycloPen™ System, followed by scleral reinforcement with AlloFlo™ Bio-Tissue implantation.

The CREST Registry study is the largest of its kind to report long-term results of this breakthrough approach using surgical micro-instrumentation and allogeneic bio-tissue to increase aqueous outflow for the lowering of intraocular pressure. The bio-interventional technique is designed to enhance uveoscleral outflow (one of the two natural outflow pathways in the eye) by creating an internal cyclodialysis channel, which is bio-reinforced for maintenance of long-term patency. This technique offers a promising new approach for patients with OAG, a condition that affects over 80 million people worldwide.

Key Findings:

• IOP Reduction: In patients with a baseline IOP > 21 mmHg, 12-month mean IOP was reduced by 39.7%. 
• Medication Reduction: At 12-months postoperatively, he average number of IOP-lowering medications decreased from 1.4 ± 1.3 to 0.8 ± 0.9, with 81.9% of patients achieving an IOP of ≤18 mmHg without the need for additional medications.
• Safety: The procedure demonstrated a favorable safety profile, with a low rate of postoperative complications. Notably, there were no vision-threatening adverse events, and only 3.2% of patients required secondary glaucoma surgery within the 12-month follow-up period to achieve target IOP.
  
  

Innovative Approach: The study highlights the use of homologous, minimally modified allogeneic scleral tissue as a bio-scaffold to reinforce the cyclodialysis cleft, enhancing cleft durability and effectiveness. Unlike implantable medical-grade metal stents or shunts, the scleral allograft bio-tissue is natural, homologous and made of 100% biologic acellular collagen matrix specifically prepared and packaged for bio-scaffolding and internal structural reinforcement.

Clinical Implications: The CycloPen^TM System with AlloFlo^TM Bio-Tissue represents a significant advancement in glaucoma surgery. By enhancing uveoscleral outflow, the procedure provides a promising alternative for patients in need of IOP reduction. With its strong safety profile and promising results, this approach could become a vital tool in managing OAG, one of the leading causes of blindness worldwide.

About the Authors: The study was published by a multidisciplinary team of experts from top institutions:

• Tsontcho Ianchulev, MD – New York Eye and Ear of Mount Sinai, New York, NY and Founder of Iantrek, Inc.
• Robert N. Weinreb, MD – Shiley Eye Institute, University of California San Diego, La Jolla, CA
• Ernesto A. Calvo, MD – Clínica de Ojos Orillac-Calvo, Panama City, Panama
• James Lewis, MD – Cataract Philadelphia, Elkins Park, PA
• Gautam Kamthan, MD – New York Eye and Ear of Mount Sinai, New York, NY
• Arsham Sheybani, MD – Washington University School of Medicine, St. Louis, MO
• Douglas J. Rhee, MD – University Hospitals, Case Western Reserve University, Cleveland, OH
• Iqbal K. Ahmed, MD – John Moran Eye Center, University of Utah, Salt Lake City, UT

About Iantrek

Iantrek, Inc. (www.iantrekmed.com) is a medical technology company founded by ophthalmic innovator Dr. Tsontcho Ianchulev, which is focused on micro- and bio-interventional solutions to advance the surgical treatment of chronic eye diseases. The company has developed a comprehensive late-stage portfolio for ophthalmic interventions and is advancing next-generation micro-surgical instrumentation and biologic tissue solutions for surgeons and patients.

Media contact:
Mike Haydin

mikehaydin@iantrekmed.com

Media contact:
Mike Haydin

mikehaydin@iantrekmed.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.